Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of RPC1063 in Relapsing Multiple Sclerosis
NCT02797015Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ozanimod in multiple sclerosis (MS) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration-Time Curve at 3 months. Started Jun 2016; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02797015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797015.